PR93673

MONTREAL, Dec. 14, 2021 /PRNewswire=KYODO JBN/ --

-- This acquisition solidifies CellCarta's leadership position in genomic

services with a unique combination of assay development and global clinical

trial sample analysis capabilities covering a comprehensive range of

established and cutting-edge genomic technologies.

CellCarta, a leading global provider of precision medicine laboratory services,

announced today the acquisition of Biogazelle ("Biogazelle"), a leader in

genomic testing solutions. Located in Ghent (Belgium), Biogazelle develops and

deploys high-end digital PCR (dPCR), quantitative PCR (qPCR) and RNASeq assays

for its pharmaceutical and biotech industry clients.

Logo - https://mma.prnewswire.com/media/1708958/CellCarta_1.jpg

Logo - https://mma.prnewswire.com/media/1708959/CellCarta_Biogazelle_2.jpg  

With decades of experience in gene expression analysis, the Biogazelle team is

uniquely positioned and skilled in the application of quantitative PCR and

digital PCR. Co-founders Jan Hellemans and Jo Vandesompele are internationally

recognized for setting standards in gene expression analysis. Biogazelle, a

Ghent University spin-off with the financial support of BNP Paribas Fortis and

the investment funds of Qbic, PMV and the Fournier-Majoie Foundation, was the

first European laboratory to offer the dPCR technology and is still at the

forefront of dPCR-based research. The group also provides dedicated RNA

sequencing workflows on clinical samples such as liquid biopsies and FFPE

tissues.

"Biogazelle's exceptional genomics expertise will enable CellCarta to further

support its clients' therapeutic development strategies, offering them key

solutions to address their clinical challenges and move their immunology and

other programs forward" said Martin LeBlanc, CEO of CellCarta. Acquiring

Biogazelle strengthens CellCarta's growth strategy to become the leading

provider of precision medicine services and will allow the organization to

extend genomic services from discovery to clinical settings. "We are very

excited to join forces with CellCarta. With both organizations driven by

scientific excellence and innovation, it's the logical next step for us to

maximally leverage our know-how and services on a truly global scale." said

Roel Sterken, CEO of Biogazelle.

While continuing to offer its current breadth of genomic services, Biogazelle

will become CellCarta's Center of Excellence for the development of complex

genomic biomarker assays. The acquisition allows CellCarta to expand its

offering to clients in fields with high demand in genomic analysis, such as

immuno-oncology and cell and gene therapy.

About CellCarta

CellCarta is a leading provider of specialized precision medicine laboratory

services to the biopharmaceutical industry. Leveraging its integrated

analytical platforms in immunology, histopathology, proteomics and genomics, as

well as related specimen collection and logistics services, CellCarta supports

the entire drug development cycle, from discovery to late-stage clinical

trials. The company operates globally with 10 facilities located in Canada,

USA, Belgium, Australia, and China.

For more information:  cellcarta.com

(https://c212.net/c/link/?t=0&l=en&o=3388542-1&h=2728571014&u=http%3A%2F%2Fwww.cellcarta.com%2F&a=cellcarta.com)

About Biogazelle  

Biogazelle offers expert laboratory services in nucleic acid quantification

(gene expression, mutation and copy number analysis, antisense oligonucleotide

screening) to support its customers in their development of diagnostics and

therapeutics. Customized workflows for clinically relevant samples – from

liquid biopsies to fixed tissues – are available. In addition, Biogazelle's

advanced RNA biomarker development program offers an end- to-end solution from

RNA biomarker panel discovery (including liquid biopsies) to the development of

a PCR-based molecular diagnostic test. Biogazelle also serves as a specialty

lab in the field of clinical trials and in routine diagnostic settings.

For more information: biogazelle.com

(https://c212.net/c/link/?t=0&l=en&o=3388542-1&h=1048809381&u=https%3A%2F%2Fservices.biogazelle.com%2F&a=biogazelle.com)

Media Contact for CellCarta: Prosek Partners, Jackie Schofield,

Jschofield@prosek.com; CellCarta, Guylaine Galipeau, Global Marketing Director,

CellCarta, ggalipeau@caprion.com; Biogazelle, Roel Sterken, CEO, Biogazelle,

+32/470.888.700, Roel.sterken@biogazelle.com

SOURCE CellCarta